Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,292 papers from all fields of science
Search
Sign In
Create Free Account
eldecalcitol
Known as:
(5z,7e)-2Beta-(3-Hydroxypropoxy)-9,10-Secocholesta-5,7,10(19)-Triene-1Alpha,3Beta,25-Triol
, 1?,25-dihydroxy-2?-(3-hydroxypropoxy)cholecalciferol
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Narrower (1)
20-epi-eldecalcitol
Broader (1)
Vitamin D
analogs & derivatives
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Eldecalcitol, an active vitamin D analog, effectively prevents cyclophosphamide-induced osteoporosis in rats
Wei Wang
,
Yuan Gao
,
+4 authors
Minqi Li
Experimental and Therapeutic Medicine
2019
Corpus ID: 199027295
Cyclophosphamide (CTX) as an alkylating agent is used for treating a range of tumor types and allergic diseases. However, high…
Expand
2018
2018
Metabolism of 2α-[2-(tetrazol-2-yl)ethyl]-1α,25-dihydroxyvitamin D3 by CYP24A1 and biological activity of its 24R-hydroxylated metabolite
K. Yasuda
,
Eri Tohyama
,
+4 authors
T. Sakaki
Journal of Steroid Biochemistry and Molecular…
2018
Corpus ID: 46798770
2017
2017
Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment
K. Iba
,
T. Sonoda
,
J. Takada
,
T. Dohke
,
T. Yamashita
Journal of Bone and Mineral Metabolism
2017
Corpus ID: 27438886
We investigated whether eldecalcitol has further significant effects on bone metabolic markers and bone mineral density (BMD) in…
Expand
2016
2016
Eldecalcitol prevents endothelial dysfunction in postmenopausal osteoporosis model rats.
K. Serizawa
,
K. Yogo
,
+4 authors
K. Endo
Journal of Endocrinology
2016
Corpus ID: 7250502
Postmenopausal women have high incidence of cardiovascular events as estrogen deficiency can cause endothelial dysfunction…
Expand
2012
2012
Osteoporosis Treatment by a New Active Vitamin D3 Compound, Eldecalcitol, in Japan
Toshio Matsumoto
Current Osteoporosis Reports
2012
Corpus ID: 24887767
Although vitamin D is used mainly as a nutritional supplement in osteoporosis treatment, its active form, 1,25-dihydroxyvitamin D…
Expand
2012
2012
Eldecalcitol normalizes bone turnover markers regardless of their pre-treatment levels
M. Shiraki
,
H. Saito
,
Toshio Matsumoto
Current Medical Research and Opinion
2012
Corpus ID: 39536518
Abstract Background: Three-year treatment with eldecalcitol has been shown to improve lumbar and total hip bone mineral density…
Expand
2012
2012
Process development for the practical production of eldecalcitol by linear, convergent and biomimetic syntheses.
N. Kubodera
,
S. Hatakeyama
Anticancer Research
2012
Corpus ID: 7959971
Eldecalcitol [1α,25-dihydroxy-2β-(3-hydroxypropoxy)vitamin D(3)], an analog of calcitriol (1α,25-dihydroxyvitamin D(3…
Expand
2012
2012
Spotlight on Eldecalcitol in Osteoporosis
M. Sanford
,
P. L. McCormack
Drugs & Aging
2012
Corpus ID: 34935488
Eldecalcitol (1α,25[OH]2-2β-(3-hydroxypropyloxy)vitamin D3; ED-71; Edirol®) is an orally administered analogue of active vitamin…
Expand
Review
2011
Review
2011
Overview of the clinical pharmacokinetics of eldecalcitol, a new active vitamin D3 derivative
M. Abe
,
N. Tsuji
,
F. Takahashi
,
Y. Tanigawara
2011
Corpus ID: 78288047
Eldecalcitol, which was developed by Chugai Pharmaceutical Co., Ltd. as a treatmentwith the potential of becoming the drug of…
Expand
Review
2009
Review
2009
D-hormone derivatives for the treatment of osteoporosis: from alfacalcidol to eldecalcitol.
N. Kubodera
Mini-Reviews in Medical Chemistry
2009
Corpus ID: 25064776
Many readers may have only a vague idea about vitamin D. This is made complicated, in part, because it is also expressed with…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE